

Paris and Toulouse, February 16, 2017

GENTICEL UPDATES ITS FINANCIAL CALENDAR FOR 2017

GENTICEL (Euronext Paris and Brussels: FR0011790542 - GTCL), a French biotechnology company today announces that the disclosure of its 2016 Annual Results is moved from the 16 March 2017 to the 28 February 2017, including the publication of its 2016 Financial Report.

28 February 2017⁽¹⁾	2016 Annual Results and 2016 Financial Report
28 February 2017	Genticel's shareholders meeting to approve the proposed contribution agreement signed with Genkyotex
27 April 2017	Business & Cash Position Update 1 st Quarter 2017
15 June 2017	Annual General Meeting in Paris, France
27 July 2017	Business & Cash Position Update 2 nd Quarter 2017
21 September 2017	2017 Half-Year Results
26 October 2017	Business & Cash Position Update 3 rd Quarter 2017

This financial calendar is for indicative purposes only and Genticel could change its publication dates if deemed necessary.

Each publication will be released after Euronext market closing.

Note (1): the publication of Genticel's 2016 Annual Results and of its 2016 Financial Report is planned on 28 February 2017, before the market opens.

About Genticel

Genticel's versatile platform, Vaxiclase, is well suited for the development of various immunotherapies. A partnership on the use of Vaxiclase as an antigen per se (GTL003) has been established with Serum Institute of India Pvt. Ltd. (Serum Institute), the largest producer of vaccine dose worldwide. This agreement covers territories in emerging markets only, and could generate up to \$57 million in revenues for Genticel, before royalties on sales. It will enable Serum Institute to develop acellular multivalent combination vaccines against a variety of infectious diseases, including whooping cough. In November 2016, the last preclinical milestone was reached, opening the path to formal preclinical testing prior to clinical development and subsequent commercialization.

On 22 December 2016, Genticel signed a contribution agreement with the shareholders of Genkyotex pursuant to which, subject to the approval of Genticel's shareholders at a meeting that will take place on 28 February 2017, Genkyotex's shareholders will contribute in kind 100% of the Genkyotex share capital (on a fully diluted basis) to Genticel, which will issue new shares in

remuneration for the contribution. Upon completion of the proposed transaction, Genkyotex's shareholders will hold 80% of Genticel's share capital & voting rights (on a non-diluted basis).

Genkyotex is developing a portfolio of NADPH oxidase (NOX) oral small molecule inhibitors, which have therapeutic potential for the treatment of multiple significant clinical indications with substantial unmet need, including fibrosis, inflammatory pain, angiogenesis, cancer growth, and neurodegeneration. Genkyotex is currently developing two clinical stage, first-in-class NOX inhibitors and is conducting research on several other pre-clinical molecules.

For more information, visit us at www.genticel.com



Disclaimer

This press release and the information it contains does not constitute an offer or solicitation to buy, sell or hold Genticel shares in any country. This press release may contain forward-looking statements by the company with respect to its objectives. These statements are based on the current estimates and forecasts of the company's management and are subject to risks and uncertainties such as the company's ability to implement its chosen strategy, customer market trends, changes in technologies and in the company's competitive environment, changes in regulations, clinical or industrial risks and all risks linked to the company's growth. These factors as well as other risks and uncertainties may prevent the company from achieving the objectives outlined in the press release. No guarantee is given on forward-looking statements which are subject to a number of risks, notably those described in the [registration document](#) filed with the French Markets Authority (the AMF) on 1 April 2015 under number R.15-015, as updated in the Document E filed with the AMF on 31 January 2017 under number E.17-004, and those linked to changes in economic conditions, the financial markets, or the markets on which Genticel is present. Genticel products are currently used for clinical trials only and are not otherwise available for distribution or sale.

EU INVESTORS

NewCap
Dušan Orešanský /
Emmanuel Huynh
+33 1 44 71 94 92
genticel@newcap.eu

US INVESTORS

LifeSci Advisors
Brian Ritchie
+1 212 915 2578
britchie@lifesciadvisors.com

MEDIA

ALIZE RP
Caroline Carmagnol /
Florence Portejoie
+33 6 64 18 99 59 / +33 6 47 38 90 04
genticel@alizerp.com